Courier Therapeutics is a biotechnology startup with a cytotoxic-lymphocyte targeting therapy platform, with a focus on making cancer-immunotherapy safer and more efficacious. Courier's first application of this targeting technology technology, CT101, is a first-in-class IL2R agonist which specifically activates the NK and CD8 T cells against cancer.
Company Details
- Founded
- 2015
- Address
- 2450 Holcombe Blvd, Houston,texas,united States
- in****@****ics.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- couriertherapeutics.com
- HQ
- Houston, Texas
Courier Therapeutics Questions
Courier Therapeutics's website is couriertherapeutics.com
Courier Therapeutics's LinkedIn profile is https://www.linkedin.com/company/courier-therapeutics
Courier Therapeutics's industry is
Biotechnology Research
Courier Therapeutics's top competitors are
Be Biopharma,
Biolum Sciences,
Alpha-9 Oncology,
Mercury,
Texas Medical Center Innovation Factory,
Tentarix Biotherapeutics,
Resonant Therapeutics,
Secretome Therapeutics,
Nkilt Therapeutics, Inc.,
March Biosciences.
Courier Therapeutics's support email address is info@couriertherapeutics.com
Courier Therapeutics's categories are Biotechnology Research
Courier Therapeutics's founding year is 2015
